Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Modern Biosciences PLC

www.modernbiosciences.com

Latest From Modern Biosciences PLC

OSE Immunotherapeutics To Bolster R&D, Post-Janssen Option

The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.

Deals Clinical Trials

Deal Watch: Sanofi And Evotec Negotiate Alliance Aimed At Improving Drug Discovery

Janssen licenses a rheumatoid arthritis program from Modern Biosciences that could address the inflammatory and bone-destruction manifestations of the disease, while Japan’s Otsuka buys Avanir on the strength of its neuroscience pipeline. Meanwhile, previously signed Astellas/Janssen and Novartis/Array agreements are terminated.

BioPharmaceutical Deals

With Latest RA Deal, Janssen Seeks To Improve Outcomes With Small Molecules

Janssen gets option to Modern’s small-molecule candidates for rheumatoid arthritis that could address both the inflammatory and bone-damaging effects of the disease. An R&D exec says the compounds could be complementary to, or used in combination with, Remicade and Simponi, or as standalone RA therapies.

BioPharmaceutical United States

JnJ enters innovative rheumatoid arthritis alliance

UK biotech Modern Biosciences (MBS) has entered into an R&D alliance and global option and license agreement with J&J's Janssen Biotech for its novel bone-protective compounds for the treatment of rheumatoid arthritis. Under the deal, facilitated by the Johnson & Johnson Innovation Centre in London, MBS will receive an upfront payment and potential milestones of up to £176m and royalties on any future sales of products arising from the alliance.

Orthopedics Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register